» Articles » PMID: 28280384

Tapentadol Extended Release for the Management of Chronic Neck Pain

Overview
Journal J Pain Res
Publisher Dove Medical Press
Date 2017 Mar 11
PMID 28280384
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of opioids in the management of chronic neck pain is still poorly investigated. No data are available on tapentadol extended release (ER). In this article, we present 54 patients with moderate-to-severe chronic neck pain treated with tapentadol ER.

Patients And Methods: Patients received tapentadol ER 100 mg/day; dosage was then adjusted according to clinical needs. The following parameters were recorded: pain; Douleur Neuropathique 4 score; Neck Disability Index score; range of motion; pain-associated sleep interference; quality of life (Short Form [36] Health Survey); Patient Global Impression of Change (PGIC); Clinician GIC; opioid-related adverse effects; and need for other analgesics.

Results: A total of 44 of 54 patients completed the 12-week observation. Tapentadol ER daily doses increased from 100 mg/day to a mean (standard deviation) dosage of 204.5 (102.8) mg/day at the final evaluation. Mean pain intensity at movement significantly decreased from baseline (8.1 [1.1]) to all time points (<0.01). At baseline, 70% of patients presented a positive neuropathic component. This percentage dropped to 23% after 12 weeks. Tapentadol improved Neck Disability Index scores from 55.6 (18.6) at baseline to 19.7 (20.9) at the final evaluation (<0.01). Tapentadol significantly improved neck range of motion in all three planes of motion, particularly in lateral flexion. Quality of life significantly improved in all Short Form (36) Health Survey subscales (<0.01) and in both physical and mental status (<0.01). Based on PGIC results, approximately 90% of patients rated their overall condition as much/very much improved. Tapentadol was well tolerated: no patients discontinued due to side effects. The use of other analgesics was reduced during the observed period.

Conclusion: Our results suggest that tapentadol ER, started at 100 mg/day, is effective and well tolerated in patients with moderate-to-severe chronic neck pain, including opioid-naïve subjects. Patients can expect a decrease in pain, an improvement in neck function, and a decrease in neuropathic symptoms.

Citing Articles

The Challenge of Managing Neuropathic Pain in Children and Adolescents with Cancer.

Coluzzi F, Stefano G, Scerpa M, Rocco M, Di Nardo G, Innocenti A Cancers (Basel). 2025; 17(3).

PMID: 39941827 PMC: 11816330. DOI: 10.3390/cancers17030460.


Opioid system and related ligands: from the past to future perspectives.

Rullo L, Morosini C, Lacorte A, Cristani M, Coluzzi F, Candeletti S J Anesth Analg Crit Care. 2024; 4(1):70.

PMID: 39390585 PMC: 11468104. DOI: 10.1186/s44158-024-00201-2.


Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.

Pergolizzi J, Magnusson P, Coluzzi F, Breve F, LeQuang J, Varrassi G Cureus. 2022; 14(6):e26000.

PMID: 35855248 PMC: 9286298. DOI: 10.7759/cureus.26000.


Pain reduction induced by tapentadol in patients with musculoskeletal chronic pain fosters better sleep quality.

Vellucci R, De Rosa G, Piraccini E Drugs Context. 2021; 10.

PMID: 33953781 PMC: 8060026. DOI: 10.7573/dic.2020-12-9.


Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children.

Howard R, Radic T, Sohns M, Eerdekens M, Wassmuth A J Pain Res. 2020; 13:3157-3170.

PMID: 33311995 PMC: 7725093. DOI: 10.2147/JPR.S272751.


References
1.
Teichtahl A, McColl G . An approach to neck pain for the family physician. Aust Fam Physician. 2013; 42(11):774-7. View

2.
Hoy D, Protani M, De R, Buchbinder R . The epidemiology of neck pain. Best Pract Res Clin Rheumatol. 2011; 24(6):783-92. DOI: 10.1016/j.berh.2011.01.019. View

3.
Carreon L, Anderson P, McDonough C, Djurasovic M, Glassman S . Predicting SF-6D utility scores from the neck disability index and numeric rating scales for neck and arm pain. Spine (Phila Pa 1976). 2010; 36(6):490-4. PMC: 3005013. DOI: 10.1097/BRS.0b013e3181d323f3. View

4.
Hu Y, Lv G, Ren S, Johansen D . Mid- to Long-Term Outcomes of Cervical Disc Arthroplasty versus Anterior Cervical Discectomy and Fusion for Treatment of Symptomatic Cervical Disc Disease: A Systematic Review and Meta-Analysis of Eight Prospective Randomized Controlled Trials. PLoS One. 2016; 11(2):e0149312. PMC: 4752293. DOI: 10.1371/journal.pone.0149312. View

5.
Suzan E, Treister R, Pud D, Haddad M, Eisenberg E . The effect of hydromorphone therapy on psychophysical measurements of the descending inhibitory pain systems in patients with chronic radicular pain. Pain Med. 2014; 16(1):168-75. DOI: 10.1111/pme.12565. View